Literature DB >> 3799814

Extensive deposition of eosinophil peroxidase in Hodgkin's and non-Hodgkin's lymphomas.

M K Samoszuk, B N Nathwani, R J Lukes.   

Abstract

To determine whether occult eosinophil degranulation occurs in lymphomas, the authors performed immunohistologic and cytochemical studies on cryostat sections from 25 consecutive lymph node biopsies. A glucose-oxidase immunohistochemical technique was employed with a murine monoclonal antibody specific for human eosinophil peroxidase (EPO). In 7 cases of Hodgkin's disease, 3 cases of T-immunoblastic sarcoma, and 1 case of small cleaved follicular center cell lymphoma with sclerosis, there was extensive and striking extracellular deposition of EPO in a granular and fibrillar pattern within the connective tissue. Similar degranulation of eosinophils was not observed in any of the benign lymph node specimens or other B-cell lymphomas. It is concluded that eosinophils extensively degranulate and release EPO in some types of lymphoma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3799814      PMCID: PMC1888483     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  11 in total

1.  Letter: Eosinophilia in bronchogenic carcinoma.

Authors:  A L Dellon; R B Hume; P B Chretien
Journal:  N Engl J Med       Date:  1974-07-25       Impact factor: 91.245

2.  Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis. Comparison with onchocerciasis.

Authors:  K M Leiferman; S J Ackerman; H A Sampson; H S Haugen; P Y Venencie; G J Gleich
Journal:  N Engl J Med       Date:  1985-08-01       Impact factor: 91.245

3.  Local eosinophilia in stroma of tumors related to prognosis.

Authors:  A Pastrnák; P Jansa
Journal:  Neoplasma       Date:  1984       Impact factor: 2.575

4.  Eosinophil-mediated mammalian tumor cell cytotoxicity: role of the peroxidase system.

Authors:  E C Jong; S J Klebanoff
Journal:  J Immunol       Date:  1980-04       Impact factor: 5.422

5.  Haematological changes in malignancy.

Authors:  R N Banerjee; R M Narang
Journal:  Br J Haematol       Date:  1967-11       Impact factor: 6.998

6.  Heterogeneity and subcompartmentalization in the distribution of eosinophils in human colonic carcinomas.

Authors:  T P Pretlow; E A Boohaker; A M Pitts; A J Macfadyen; E L Bradley; T G Pretlow
Journal:  Am J Pathol       Date:  1984-08       Impact factor: 4.307

7.  Deposition of eosinophil cationic protein in granulomas in allergic granulomatosis and vasculitis: the Churg-Strauss syndrome.

Authors:  P C Tai; M E Holt; P Denny; A R Gibbs; B D Williams; C J Spry
Journal:  Br Med J (Clin Res Ed)       Date:  1984-08-18

8.  Malignant tumor and eosinophils. I. Prognostic significance in gastric cancer.

Authors:  K Iwasaki; M Torisu; T Fujimura
Journal:  Cancer       Date:  1986-09-15       Impact factor: 6.860

9.  Thyroid carcinoma and eosinophilia.

Authors:  P Van Crombrugge; R Pauwels; M Van der Straeten
Journal:  Ann Clin Res       Date:  1983-06

10.  Deposition of eosinophil granule major basic protein onto microfilariae of Onchocerca volvulus in the skin of patients treated with diethylcarbamazine.

Authors:  G M Kephart; G J Gleich; D H Connor; D W Gibson; S J Ackerman
Journal:  Lab Invest       Date:  1984-01       Impact factor: 5.662

View more
  10 in total

1.  Phase I imaging study of Hodgkin's disease and non-Hodgkin's lymphomas with radiolabeled antibody to eosinophil peroxidase.

Authors:  M Samoszuk; A L Anderson; F Wang; P Braunstein; H Majmundar; J Ravel; E Ramzi; L Slater
Journal:  Cell Biophys       Date:  1992 Aug-Dec

2.  Occult deposition of eosinophil peroxidase in a subset of human breast carcinomas.

Authors:  M K Samoszuk; V Nguyen; I Gluzman; J H Pham
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

3.  Mature eosinophils stimulated to develop in human-cord blood mononuclear cell cultures supplemented with recombinant human interleukin-5. II. Vesicular transport of specific granule matrix peroxidase, a mechanism for effecting piecemeal degranulation.

Authors:  A M Dvorak; S J Ackerman; T Furitsu; P Estrella; L Letourneau; T Ishizaka
Journal:  Am J Pathol       Date:  1992-04       Impact factor: 4.307

4.  Morphological and immunohistochemical studies of Hodgkin's disease in the spleen.

Authors:  M Takeshita; S Falk; J Schwetje; H J Stutte
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

5.  Eosinophils generate brominating oxidants in allergen-induced asthma.

Authors:  W Wu; M K Samoszuk; S A Comhair; M J Thomassen; C F Farver; R A Dweik; M S Kavuru; S C Erzurum; S L Hazen
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

6.  Intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and regulated on activation normal T cell expressed and secreted are expressed by human breast carcinoma cells and support eosinophil adhesion and activation.

Authors:  S Ali; J Kaur; K D Patel
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

7.  Increased blood clotting, microvascular density, and inflammation in eotaxin-secreting tumors implanted into mice.

Authors:  Michael Samoszuk; Tom Deng; Mark J Hamamura; Min-Ying Su; Nicholas Asbrock; Orhan Nalcioglu
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

8.  Cytophilic and cytotoxic properties of human eosinophil peroxidase plus major basic protein.

Authors:  M K Samoszuk; A Petersen; F Gidanian; C Rietveld
Journal:  Am J Pathol       Date:  1988-09       Impact factor: 4.307

9.  Quantitative Analysis of Tumor-associated Tissue Eosinophilia in Recurring Bladder Cancer.

Authors:  Hristo Popov; Ivan S Donev; Peter Ghenev
Journal:  Cureus       Date:  2018-09-10

10.  Eosinophil peroxidase over-expression predicts the clinical outcome of patients with primary lung adenocarcinoma.

Authors:  Liang Ye; Hongying Wang; Huijuan Li; Hongbing Liu; Tangfeng Lv; Yong Song; Fang Zhang
Journal:  J Cancer       Date:  2019-01-29       Impact factor: 4.207

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.